C4 Therapeutics, Inc. — Director's Dealing 2021

Apr 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-04-05

Reporting Person: Crystal Adam (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-05	Common Stock	M	15000	$6.50	Acquired	15000	Direct
2021-04-05	Common Stock	S	4121	$37.1581	Disposed	10879	Direct
2021-04-05	Common Stock	S	10879	$38.0005	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-05	Common Stock	$6.50	M	15000	Disposed	2029-04-08	Common Stock (15000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.545 to $37.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.59 to $38.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.